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seven transmembrane helical receptors (7TmRs) modulate cell function via different types 
of G proteins, often in a ligand-specific manner. Class A 7TmRs harbour allosteric vestibules 
in the entrance of their ligand-binding cavities, which are in the focus of current drug discovery. 
However, their biological function remains enigmatic. Here we present a new strategy for 
probing and manipulating conformational transitions in the allosteric vestibule of label-free 
7TmRs using the m2 acetylcholine receptor as a paradigm. We designed dualsteric agonists 
as ‘tailor-made’ chemical probes to trigger graded receptor activation from the acetylcholine-
binding site while simultaneously restricting spatial flexibility of the receptor’s allosteric 
vestibule. our findings reveal for the first time that a 7TmR’s allosteric vestibule controls the 
extent of receptor movement to govern a hierarchical order of G-protein coupling. This is a new 
concept assigning a biological role to the allosteric vestibule for controlling fidelity of 7TmR 
signalling. 
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Seven transmembrane helical receptors (7TMRs; G-protein-coupled receptors) are embedded into the membrane of almost all cells and are essential for orchestrating the function of cells 
in order to maintain homoeostasis of the organism and its adapta-
tion to environmental changes. In addition, modulation of 7TMR 
function by drugs is a mainstay for the prevention and treatment 
of disease1. The human genome encodes about 800 7TMRs with 
the rhodopsin-like class A receptors representing the quantitatively 
dominating subfamily, which include aminergic and cholinergic 
receptors2. 7TMR activation by an extracellular stimulus is commu-
nicated to the cell by a conformational rearrangement of the intra-
cellular domain region that mediates recruitment and activation of 
adaptor proteins. These proteins control the activity of intracellular 
signalling pathways and include guanylnucleotide-binding proteins 
(G proteins) and β-arrestins3.
Heterotrimeric G proteins are subdivided into four families based 
on sequence homologies and functional similarities of their Gα 
subunits, Gi/o, Gs, Gq/11 and G12/13 (ref. 4). These can be addressed 
selectively, but often an endogenous activator-bound 7TMR has effi-
cacy to activate more than one class of G protein, which is referred 
to as promiscuous signalling. Remarkably, especially from a thera-
peutic point of view, chemically modified artificial ligands may 
engender more precise signalling than the endogenous activator 
molecule, which is designated as biased signalling, functional selec-
tivity or signal trafficking5–7. It is likely that the signalling repertoire 
of a 7TMR corresponds to ensembles of possible conformations of 
the receptor protein, and that a biased activator allows only for a 
subset of possible receptor conformations8.
Crystal structures of 7TMRs give fascinating insight into the 
conformational rearrangements that accompany inactive-to-active 
transitions9–11. However, the molecular principles by which a recep-
tor protein translates the chemical properties of a ligand into a sig-
nalling fingerprint are still unresolved12. Accumulating evidence 
suggests that there is no consensus sequence for adaptor protein- 
coupling specificity on the level of the intracellular domains13, and, in 
line with this notion, signalling is often promiscuous. On the level of 
the helical bundle region, 7TMR structure is highly conserved, which 
would correspond well to a general activation mechanism14 but not 
to coupling selectivity. In the extracellular loop region, however, there 
is rather high variability between primary structures. Remarkably, a 
ligand-dependent conformational coupling from the orthosteric site 
to the extracellular loop region has recently been described15.
Intriguingly, class A 7TMRs harbour allosteric vestibules in the 
extracellular entrance of their ligand-binding cavities, which receive 
high attention as new targets for drug discovery16. However, until 
now, their biological function is poorly understood. The question 
therefore arises whether the extracellular domains hold a function 
in controlling intracellular signalling of a 7TMR.
We took advantage of a new strategy for probing the allosteric 
vestibule’s role for signal trafficking using the M2 acetylcholine 
(ACh) receptor as a paradigm for small ligand 7TMRs. Muscarinic 
ACh receptors are important targets for novel drugs with improved 
selecitivtiy17, and in particular, fundamental insights of 7TMR 
function have first been achieved with this receptor. These include 
the discovery of 7TMR allosterism18, the establishment of the ter-
nary complex model of allosteric interactions19, its proof with a 
radiolabelled allosteric probe20 and the identification of allosteric 
key epitopes as well as their spatial orientation within the allosteric 
vestibule21–23. We designed a set of ‘tailor-made’ chemical probes, 
referred to as dualsteric agonists24, to trigger graded receptor 
activation from the ACh-binding site (that is, the orthosteric site) 
while simultaneously restricting spatial flexibility of the receptor’s 
extracellular allosteric vestibule.
Evaluation of probe actions in this study in a broad array of 
signalling readouts, including those in a space-providing ‘res-
cue mutant’, show that the allosteric vestibule of the M2 receptor 
controls the extent of receptor movement thereby governing a 
hierarchical order of intracellular adaptor protein recruitment. This 
is a new concept assigning an unprecedented biological role to the 
allosteric vestibule for controlling fidelity of receptor signalling of a 
small molecule 7TMR.
Results
Strategy for new chemical tool design. Muscarinic ACh receptors 
belong to the class A of G-protein-coupled receptors, which 
bind their endogenous agonist deep in the ligand-binding cleft 
lined by transmembrane helical domains25–27. Asp1033.32 (Fig. 1a) 
serves as a docking point for the positively charged nitrogen of 
ACh. Iperoxo ((1) in Fig. 1b), the orthosteric building block of 
the dualsteric compounds, is a super-potent muscarinic agonist 
characterized by an affinity-enhancing ∆2-isoxazoline ring system 
and was re-synthesized as previously described28. Iperoxo is 100-
fold more potent than ACh as reported below and was chosen as the 
orthosteric building block of the dualsteric probes to ensure high-
fidelity receptor activation via the orthosteric-binding site. To study 
the role of the allosteric substituent for signalling (shaded grey in 
Fig. 1b), iper-6 ((2) in Fig. 1b) was synthesized (Supplementary 
Methods), which carries the linker chain without the spacious 
allosteric building blocks. The allosteric phthalimide building block 
contained in iper-6-phth ((3) in Fig. 1b) has no efficacy for receptor 
activation29 and binds to M2-W4227.35 at the beginning of TM7 
and to M2-Y1775.32 in the extracellular loop 2 (Fig. 1a)21–23. These 
two amino acids are located opposite to each other in the depth of 
the allosteric vestibule in close vicinity to the subjacent orthosteric 
site23. The crystal structure of the inactive antagonist-bound M2 
receptor proves the location of M2-Y1775.32 and M2-W4227.35 
outside of and above the aromatic cage that encloses the orthosteric 
ligand, respectively25. Docking simulations show that the allosteric 
building block protrudes to the level of M2-W4227.35 (ref. 24). If 
this binding topography causes a signalling bias, enlargement of the 
substituent to naphthalimide (in iper-6-naph, (5) in Fig. 1b), which 
by itself also has no efficacy for receptor activation29, should further 
impair signalling. Iper-6-phth and iper-6-naph were re-synthesized 
precisely as described previously24. In contrast, elongation of the 
hexamethylene middle chain to octamethylene, as realized in 
the newly synthesized iper-8-phth and iper-8-naph ((4) and (6) in 
Fig. 1b, respectively, Supplementary Methods), would be expected 
to restore the signalling by shifting the spacious substituent outward 
of this critical region.
Probe binding to cell surface hM2-receptors. Ligand–receptor 
interactions in live CHO cells transfected to stably express hM2 
receptors (CHO-hM2 cells) were measured using the non-permeant 
orthosteric radioligand [3H]-N-methylscopolamine ([3H]NMS) to 
clarify prerequisites for the analysis of probe signalling.
Dualsteric ligands may principally bind in two orientations, the 
dualsteric mode (pose 1 in Fig. 1c) and the purely allosteric mode 
(pose 2 in Fig. 1c). As receptor activation is encoded by their orthos-
teric agonist building block, the probes of this study will be ago-
nistic only in the dualsteric posture. Iper-6-naph was chosen for 
validation of dualsteric binding, because, first, the naphthalimide 
residue has a higher allosteric M2 receptor-binding affinity than 
phthalimide, and, second, the six-membered linker is less suited 
for an unconstrained dualsteric receptor interaction than the eight-
membered linker (see below). Equilibrium and dissociation binding 
experiments revealed a pronounced preference of iper-6-naph for 
the dualsteric pose relative to the allosteric pose (Fig. 2).
M2 receptors prefer coupling to Gi over Gs proteins30,31 (Fig. 1c). 
Pretreatment of CHO-hM2 cells with pertussis toxin (PTX) to 
silence Gi- and disclose Gs coupling does not affect binding of 
iper-6-naph and other probes. Binding data are compiled in 
Supplementary Fig. S1 and Supplementary Table S1.
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Dualsteric probes induce structure-dependent Gi bias. 7TMR pro-
teins can be considered as dynamically fluctuating macromolecules 
that adopt ensembles of tertiary conformations5. Label-free tech-
niques use native receptor proteins thus ensuring natural conforma-
tional flexibility and sensitivity to probe actions. Recently, we estab-
lished dynamic mass redistribution (DMR) as a novel and powerful 
label-free technology to identify G-protein-dependent signalling 
in live cells32,33. Of note, 7TMR signalling along a given pathway 
may yield cell type-dependent DMR responses33. Here, we applied 
CHO-hM2 cells. As CHO cells do not generate ACh esterase34, they 
are well suited to quantify DMR responses to the endogenous trans-
mitter ACh (Fig. 3a–d). ACh is known to activate Gi and Gs signal-
ling of M2 receptors30,31. Native CHO-hM2 cells respond to ACh 
in a concentration-dependent manner with brisk positive DMR 
(Fig. 3a), which suggests Gi pathway activation32,33. Cells pretreated 
with PTX to chemically knockout Gi proteins respond to ACh with 
negative DMR (Fig. 3b). As this signal is completely sensitive to 
cholera toxin (CTX), which is known to mask Gs-mediated signal-
ling32,33, the negative DMR reflects Gs pathway activation (Supple-
mentary Fig. S2). Therefore, positive DMR observed in unpretreated 
cells includes Gi- and Gs-mediated signalling events. However, the 
brisk peak DMR seen in unpretreated cells represents Gi activation 
as, first, this peak is still present in CTX-pretreated cells (Fig. 3c) 
and, second, potencies of ACh for inducing positive peak DMR in 
the absence and presence of CTX are in the same range (Fig. 3d, 
control: pEC50 = 8.09 ± 0.13; CTX: pEC50 = 7.49 ± 0.16; P = 0.02, 
unpaired t-test). The small, albeit significant, difference in poten-
cies is likely to be caused by cellular adaptation to the CTX-induced 
rise of intracellular cyclic AMP (cAMP). In contrast, the potency of 
ACh for Gs activation (pEC50 = 6.01 ± 0.19) is 100-fold lower com-
pared with positive peak DMR and 30-fold lower relative to positive 
peak DMR in CTX-pretreated cells (P < 0.001, one-way analysis of 
variance (ANOVA) with Dunnett’s post test). Taken together, peak 
DMR in unpretreated cells represents Gi activation.
Dualsteric probes exhibit a Gi over Gs signalling bias compared 
with ACh and iperoxo (Fig. 3e–h), which induce equieffective pro-
miscous Gi and Gs signalling (compare DMR peaks in Fig. 3, panels 
e with g and f with h, respectively). Noteworthy, pretreatment with 
PTX did not affect receptor density (Bmax-PTX = 89% of Bmax- 
control, P = 0.75, unpaired t-test). Relative to these agonists, iper-6 
has comparable maximum effects (Fig. 3g,h). In contrast, iper-6- 
phth and iper-8-phth, although being almost equieffective to 
orthosteric agonists with respect to Gi-DMR (Fig. 3e), hardly 
induce Gs-DMR (Fig. 3f). Of note, the middle chain-elongated iper-
8-phth is more competent for Gs-DMR than iper-6-phth (Fig. 3f). 
In case of the spacious iper-x-naph analogues, even Gi-DMR is 
compromised with iper-6-naph (Fig. 3g), whereas the middle chain- 
elongated iper-8-naph clearly achieves maximum Gi-DMR (Fig. 3g). 
As found with iper-x-phth analogues, Gs-DMR is more compro-
mised than Gi-DMR, especially in case of iper-6-naph (Fig. 3h) where 
Gs signalling is virtually silenced. Iper-8-naph only partially acti-
vates the Gs pathway (Fig. 3h), comparable to iper-8-phth (Fig. 3f). 
Peak DMR-values are enumerated in Supplementary Table S2.
Taken together, the DMR findings reveal that Gs pathway 
activation by the hM2 receptor is far more sensitive to spacious 
allosteric substituents than Gi activation. In addition, probes 
indicate that the position of the spacious allosteric substituent 
within the extracellular binding cleft of the receptor protein is 
crucial for signalling.
Quantification of the probes’ Gi bias. DMR measurements point to 
a structure-dependent signalling bias. We used standard Gi and Gs 
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Figure 1 | Receptor binding poses of dualsteric probes. (a) snake-like plot of the outer loop region of the muscarinic m2 receptor along with the flanking 
alpha-helical domains. Arrows indicate essential epitopes for orthosteric (green) and allosteric (red) ligand binding. (b) Dualsteric hybrid design: the 
super high-affinity orthosteric muscarinic agonist iperoxo is linked via a hexamethylene- or octamethylene-spacer with allosteric inverse agonistic 
phthalimide or naphthalimide moieties. (c) Receptor binding poses of dualsteric probes in the absence (1,2) and presence (3) of an orthosteric ligand. 
With the hybrid design of this study, only the dualsteric binding mode (1) leads to receptor activation and downstream signalling. The coupling efficiency 
τ quantifies the efficacy with which agonist-occupied receptors activate Gi and Gs signalling. The coupling of either Gi or Gs proteins to the m2 receptor 
affects the binding constant KA of the dualsteric agonist.
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signalling readouts that are close downstream to receptor activation 
for quantifying the probes’ signalling bias.
[35S]GTPγS binding in membrane suspensions of CHO-hM2 
cells reflects replacement of GDP by GTP at G protein α subunits 
as a consequence of receptor activation (Fig. 4a). This assay almost 
exclusively captures Gi activation35. Intracellular cAMP formation 
in probe-activated CHO-hM2 cells pretreated with PTX displays 
activation of the Gs pathway (Fig. 4b).
Regarding maximum effects, Fig. 4a,b shows—as observed in the 
DMR measurements—that iper-6-phth and even more so iper-6-
naph are compromised with respect to the Gs assay relative to the Gi 
assay. Again, the middle chain-elongated derivatives show increased 
efficacy for Gs signalling (Fig. 4a,b and Supplementary Table S3).
The bias plot36 (Fig. 4c) compares signalling via the Gi and Gs 
route at equal concentrations of test compound over the range of 
applied concentrations. The respective maximum effects of ACh 
define 100%. The hyperbolic curve of ACh reflects its preference for 
Gi activation, which is designated as system bias. Relative to this 
system bias, all test compounds, except iperoxo, reveal a stronger Gi 
bias. On the receptor level, this may result from a higher affinity ratio 
of binding to Gi- versus Gs-coupled receptors. In addition or alterna-
tively, the efficacy τ of an agonist-bound receptor may be higher for 
signalling via the Gi instead of the Gs pathway. Global fitting of the 
functional data (Fig. 4a,b) with the operational model of agonism37 
provides measures for both the binding constant (KA) and the effi-
cacy (τ) of the respective agonists. The τ/KA-ratio38 (transduction 
coefficient) encompasses both potential mechanisms of bias (for 
τ/KA-ratios for both pathways normalized on ACh (∆log(τ/KA)) see 
Table 1). ∆∆log(τ/KA)-values38 (Fig. 4d, Table 1) eliminate system 
bias and indicate true test compound bias relative to ACh. In gen-
eral, dualsteric agonists are significantly Gi biased (Fig. 4d). Iper-8-
naph is an exception; this compound has clearly lower efficacy on 
the Gs pathway (Fig. 4b) than ACh, which, however, is compensated 
by a higher binding affinity (low KA-value; Supplementary Table S4). 
Figure 4e focusses on the efficacy component of ligand bias. Plotted 
is the efficacy log τ of agonist-bound receptors for activating Gi and 
Gs signalling. The iper-6-naph-bound receptor has lowest signalling 
efficacy. The latter is restored by replacement of the naph-residue by 
the less voluminous phth-residue and even more by linker elonga-
tion from C6 to C8. Iper-8-naph and iper-8-phth attain an upper 
level of Gi activation, which is not surpassed by ACh and iperoxo, 
but are still clearly inferior with respect to Gs activation. Shortening 
of the dualsteric agonists to iper-6 and further to iperoxo then step-
wise restores Gs signalling efficacy. These findings corroborate the 
notion that Gs signalling efficacy of the agonist-bound M2 receptor 
is more sensitive to the allosteric residues of dualsteric probes than 
Gi signalling efficacy (Supplementary Table S4).
Middle chain elongation restores signalling at different levels. 
As 7TMR ligands may have widely differing signalling competence 
depending on pathways (for review see refs 39,40), we investigated 
the probes’ signalling pattern in a set of additional readouts.
First, we focused on the receptor’s intracellular loops, as these 
mediate receptor contact with adaptor proteins. We used a FRET-
sensor-hM2-receptor, stably expressed in HEK293 cells, that has an 
enhanced cyan fluorescent protein (eCFP) fused to its C-terminus 
and a FlAsH-binding domain introduced within the third intracel-
lular loop beneath transmembrane domain TM5, respectively41–44  
(Supplementary Methods).
Agonist-induced conformational transitions of the inner loop 
region were diminished in the case of iper-6 and not significantly 
different from baseline in the case of iper-6-phth and iper-6-naph 
(Fig. 5a). Intracellular loop movements reappeared with the iper-
8-X compounds. Thus, the allosteric substituents introduced into 
the orthosteric iperoxo and pointing to the extracellular surface of 
the receptor protein severely restrict inner loop region dynamics. 
Noteworthy, shifting the spacious residues further outward in the 
allosteric region by middle chain elongation unleashes orthosteric 
agonist-like intracellular loop rearrangement.
Next, we examined conformational transitions of the Gi protein 
(Fig. 5b and Supplementary Methods). Therefore, the activation- 
promoted rearrangement of the α-subunit relative to the βγ-subunit 
was analysed using a protein–protein-interaction-based biolumi-
nescence resonance energy transfer (BRET) assay45 in COS7-cells. 
These were transiently co-transfected with the hM2 receptor and the 
Renilla luciferase-tagged Gαi1-subunit along with Gβ and a GFP-
tagged γ-subunit. All probes induce a conformational rearrange-
ment of the Gi protein with the iper-8-X compounds displaying a 
higher efficacy than the respective iper-6-X probes. Compared with 
the inner loop-assay (Fig. 5a), efficacies are generally higher, which 
is likely due to a receptor reserve in the latter assay. Taken together, 
restricted capacity of the dualsteric probes for inducing inner loop 
rearrangement translates into diminished G-protein activation.
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Figure 2 | Verification of dualsteric probe binding in live CHO-hM2  
cells. Iper-6-naph is chosen for verification of dualsteric binding in  
whole cells, because, first, the naph-building block has a higher binding 
affinity to the allosteric binding area than the phth-binding block and, 
second, signalling of iper-6-naph is most compromised among all 
probes, which could theoretically be due to a low probability of dualsteric 
binding (pose 1). ‘6-naph’ (equivalent to compound ‘A2’ in ref. 24 and 
re-synthesized precisely as described therein) serves as a surrogate for 
the allosteric building block of iper-6-naph. (a) After having determined 
radioligand ([3H]nms)-binding characteristics (pose 4), the affinity of 
iper-6-naph for the radioligand-bound receptor (pose 3) is derived from 
probe-induced inhibition of radioligand-dissociation (EC50, diss = α×KB, allo). 
As to be expected iper-6-naph and 6-naph have almost the same affinity 
to the [3H]nms-bound receptor. (b) Interaction of 6-naph with the 
radioligand under equilibrium binding conditions and analysis based on the 
ternary complex model is taken to represent the affinity of iper-6-naph  
for the purely allosteric binding pose 2. (c) Interaction of iper-6-naph 
with the radioligand under equilibrium conditions and data analysis 
including binding constants for poses 2 and 3 (modified after55) yields 
the binding constant for the dualsteric mode (pose 1). (d) The ratio of 
binding constants for poses 1 and 2 displays the concentration-dependent 
fractional receptor occupancy of iper-6-naph (black curve) in the dualsteric 
(green curve, 84%) and allosteric (red curve, 16%) binding mode. Error 
bars indicate s.e.m. of 6–12 replicates from 2–4 independent experiments.
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ERK1/2 phosphorylation is triggered by the βγ-subunit of 
active Gi proteins46. The active βγ-subunit directly interacts with 
phosphoinositide 3-kinase γ inducing a series of downstream 
events resulting in increased ERK1/2-phosphorylation and eventu-
ally in modified gene expression47. M2 receptor-mediated ERK1/ 
2-phosphorylation in CHO cells is exclusively Gi-dependent, as it 
is completely abolished after PTX pretreatment (Supplementary 
Fig. S3). As iper-6-X compounds are less efficacious than their 
middle chain-elongated iper-8-X fellows (Fig. 5c), the structure-
dependent efficacy pattern is similar to that encountered in Gi  
readouts (Figs 3e,g and 4a).
β-Arrestin recruitment was studied in HEK293 cells stably 
expressing GFP-β-arrestin2 and transiently coexpressing the 
hM2–Rluc fusion protein and GRK2 (Supplementary Methods). The 
construct has full signalling competence with respect to Gi and Gs 
signalling (Supplementary Fig. S4). β-Arrestin recruitment is par-
tially restored in the middle chain-elongated derivatives iper-8-X 
relative to the hexamethylene compounds iper-6-X (Fig. 5d).
Taken together, dualsteric probe-induced reduction of the 
receptor’s allosteric domain flexibility translates into restricted 
intracellular loop rearrangement and, subsequently, to impaired 
downstream signalling events.
An allosteric space ‘rescue mutation’ boosts signalling. In order 
to further test the hypothesis that M2 receptor signalling critically 
depends on a conformational narrowing in the core region of the 
receptor’s allosteric vestibule near M2-W4227.35, we replaced the 
spacious tryptophan by the small alanine. This should unleash 
signalling of the dualsteric agonists. We focused on iper-6-phth 
and iper-6-naph, as these probes displayed the weakest signalling 
efficacy in the preceding experiments.
M2-W4227.35A reduces binding affinities of ACh (Fig. 6a) and 
iperoxo (Fig. 6b). The respective potencies for G-protein activation 
are diminished to the same extent (Fig. 6c,d). Both, iper-6-phth and 
iper-6-naph lose binding affinity and, to a lesser extent, potency at 
mutant receptors (Fig. 6a–d and Supplementary Table S5). Most 
importantly, the allosteric mutation leads to a gain in dualsteric 
probes’ efficacy (Fig. 6c,d). As the surface expression of mutant 
receptors was about one-third lower compared with wild type (Sup-
plementary Fig. S5), evaluation based on maximum effects would 
even underestimate the ligand’s true capacity for receptor activation. 
Comparison of log τ-values reveals that efficacy for Gi activation of 
iper-6-phth and iper-6-naph in the mutant are indistinguishable 
from that of iperoxo (Fig. 6e).
Probe-induced maximum DMR was compared between CHO-
hM2 cells (Fig. 7a,b) and CHO-hM2-W4227.35A cells (Fig. 7b,c). 
Both, PTX pretreatment and the allosteric mutation lead to a pro-
nounced loss of orthosteric agonist potency (Figs 3d and 6c,d). Under 
these conditions, iperoxo—due to its high potency—still achieves a 
clear maximum effect on the Gs pathway at the mutant receptor and 
was therefore used instead of ACh to define full efficacy and bal-
anced agonism (for original DMR traces see Supplementary Fig. S6). 
As reported above (Fig. 6 and Supplementary Table S5), dual-
steric probe potency is little affected by the mutation. Probes were 
applied at maximally effective concentrations with respect to both, 
Gs and Gi pathway activation. Under these conditions, maximum 
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Figure 3 | Cellular DMR reveals structure-dependent Gi bias of dualsteric probes. (a–c) shown are baseline-corrected DmR responses measured as 
wavelength shifts (pm) and recorded over time after addition of indicated concentrations of ACh in non-pretreated CHo-hm2 cells (control, a) and either 
PTX (b)- or CTX (c)-pretreated CHo-hm2 cells (means and s.e.m.) from one representative out of at least four independent experiments conducted in 
quadruplicates. (a) ACh exposure of control cells induces concentration-dependent positive DmR with peaks reflecting Gi signalling. (b) Pretreatment 
with the Gi inhibitor PTX (100 ng ml − 1, 16–24 h) reveals negative DmR reflecting Gs signalling. (c) masking Gs-dependent signalling by CTX pretreatment 
(100 ng ml − 1, 8 h) induces positive DmR followed by sustained plateaus at higher concentrations. (d) Concentration-effect curves of ACh-induced peak 
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iper-6-naph 100 µm, iper-8-naph 10 µm and iper-6 100 µm. Representative data (means and s.e.m.) of at least three independent experiments  
conducted in quadruplicates.
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effects can be taken to reflect coupling efficacy τ. In the mutant 
receptor, maximum Gs-DMR induced by the probes is increased in 
case of the iper-6-X compounds and iper-8-phth (Fig. 7b). Only in 
the case of iper-8-naph, which has the highest Gs-DMR among the 
dualsteric probes at wild-type hM2 receptor, a further increase in 
maximum Gs-DMR was not observed. The most impressive gain in 
Gs pathway activation is found with iper-8-phth, yet full Gs signal-
ling is not achieved in the mutant (Fig. 7b,c). As mentioned previ-
ously (Fig. 6), the mutant receptor also allows for a gain in efficacy 
for Gi signalling, which is most pronounced for iper-6-naph (see 
ordinates in Fig. 7a,c).
The partial agonists pilocarpine and McN-A-343 are included 
in Fig. 7 for comparison. Pilocarpine has an orthosteric binding 
topography29, McN-A-343 is a bitopic allosteric/orthosteric partial 
agonist at hM2 receptors48. Pilocarpine and McN-A-343 respond 
differently to the mutation compared with the dualsteric probes 
(Fig. 7a,c), as the efficacy of pilocarpine is almost completely lost, 
whereas the efficacy of McN-A-343 does not differ from hM2 wild 
type (all Emax values are enumerated in Supplementary Table S6). 
These findings underpin that the dualsteric probes exhibit a unique 
molecular mechanism of receptor interaction.
Importantly, the increase in Gi/Gs signalling of the dualsteric 
compounds in CHO-hM2-W4227.35A cells (Fig. 7c) strictly follows 
the hyperbolic relationship defined for CHO-hM2 cells (Fig. 7a). 
Obviously, nearly full efficacy for Gi signalling is required before 
additional Gs signalling can emerge. We conclude that the receptor 
conformation mediating Gs signalling is reached via an intermedi-
ate conformation, the signalling efficacy of which is confined to Gi 
activation.
Discussion
In recent years, accumulating evidence suggests that signalling 
promiscuity is a general principle of 7TMR biology. For many 
7TMRs, ligands are available that selectively activate a subset of 
signalling pathways3,40. The mechanisms underlying multiple sig-
nalling pathway activation and functional selectivity are far from 
being understood12. Applying a new methodological approach, this 
study provides hitherto unprecedented insights into the role of the 
allosteric vestibule for the discrimination between signalling path-
ways of a 7TMR. In order to allow for the subtle conformational 
transitions that underlie signalling promiscuity and selectivity8, we 
laid emphasis on the study of a native, unlabelled receptor protein. 
To probe the role of the receptor’s extracellular domain for discrim-
inating signalling pathway activation, we applied small molecules 
designed to interfere in a graded manner with activation-related 
extracellular domain rearrangements. Our study shows that this 
strategy allows capturing conformational dynamics underlying 
differential signalling pathway activation.
Several studies show that extracellular loops, especially the 
second extracellular loop, take part in the binding and activation of 
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Figure 4 | Quantifying the Gi bias of dualsteric probes. (a) m2 receptor-
mediated Gi protein activation is reflected by [35s]GTPγs binding to 
membranes of CHo-hm2 cells. maximum G-protein activation induced by 
ACh was set 100%. Data are means ± s.e.m. from at least four independent 
experiments conducted in quadruplicates. (b) m2 receptor-mediated 
Gs activation is reflected by an increase of intracellular cAmP in CHo-
hm2 cells pretreated with PTX (50 ng ml − 1, 16–24 h). maximum cAmP 
formation induced by ACh was set 100%. Data are means ± s.e.m. from 
at least three independent experiments conducted in quadruplicates. 
Concentration-effect curves were obtained by global fits applying  
the operational model of agonism37 to the data points in a and b.  
(c) Visualization of ligand bias: fractional [35s]GTPγs binding and cAmP 
accumulation (a,b) are plotted for equal concentrations of the respective 
agonists on the ordinate and abcissa, respectively. The hyperbolic shape 
of the ACh graph indicates system bias. The Gi protein is preferred by the 
m2 receptor. Ligands whose bias exceeds system bias display graphs that 
differ substantially in their curvature radii and the height of their plateaus. 
(d) Quantification of ligand bias: ∆∆log(τ/KA) values compensate for 
system bias and display true ligand bias relative to Ach, which is taken 
as balanced agonist. Ligands with positive values are Gi biased when the 
limits of their 95% confidence intervals (CIs) do not contain zero. Data  
are means with 95% CIs. (e) Efficacies of the agonist-occupied receptor  
to activate the Gi pathway (log τ(Gi)) and the Gs pathway (log τ(Gs))  
are plotted on the ordinate and abcissa, respectively. Log τ values are 
derived from global fits applying the operational model to the data points  
in a and b. Data are means ± s.e.m.
Table 1 | Parameters characterizing ligand bias of muscarinic 
agonists.
Ligand [35S]GTPS 
binding
cAMP 
accumulation
Log bias
∆log(τ/KA), 
95% CI
∆log(τ/KA), 
95% CI
∆∆log(τ/KA), 
95% CI
ACh 0 0 0
Iperoxo (1) 2.11, 1.83 to 
2.38
2.25, 1.84 to 
2.66
 − 0.15,  − 0.59 to 
0.29
Iper-6 (2)  − 0.26,  − 0.51 
to  − 0.01
 − 0.78,  − 1.09 
to  − 0.46
0.52, 0.13 to 
0.90
Iper-6-phth (3) 0.37, 0.11 to 
0.62
 − 0.74,  − 1.15 
to  − 0.33
1.10, 0.68 to 
1.53
Iper-6-naph (5) 0.63, 0.35 to 
0.91
 − 0.62,  − 1.03 
to  − 0.21
1.25, 0.81 to 
1.69
Iper-8-phth (4) 1.21, 1.02 to 
1.41
0.36,  − 0.05 to 
0.77
0.86, 0.47 to 
1.25
Iper-8-naph (6) 1.78. 1.50 to 
2.06
1.52, 1.11 to 1.93 0.26,  − 0.18 to 
0.70
CI, confidence interval.
Transduction coefficients ∆log(τ/KA) relative to the reference agonist ACh with 95% confi-
dence intervals (95% CI) for the Gi and the Gs pathway as represented by [35s]GTPγs binding 
and cAmP accumulation assays, respectively. ∆∆log(τ/KA) denotes true ligand bias.
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rhodopsin-like class A 7TMRs49. Until now, however, the molecular 
events have not been elucidated by which the extracellular region is 
functionally linked with the intracellular control of adaptor protein 
recruitment and the consecutive differential activation of signalling 
pathways. Here we show for the first time that relay of signalling 
triggered by orthosteric agonist binding critically depends on spa-
tial freedom for concurrent extracellular conformational transi-
tions. Allosteric substituents—attached to the orthosteric agonist 
iperoxo—that protrude into the free volume of the extracellular 
loop region severely hamper signalling of the M2 receptor.
Structure–activity relationships of dualsteric probes and employ-
ment of the hM2-W4227.35A mutant receptor allowed to narrow 
down a critical region of the M2 receptor in the vicinity of W4227.35, 
which is located above the orthosteric-binding pocket at the con-
tact between the third extracellular loop and the beginning of TM7 
(ref. 25). This epitope is conserved among the five subtypes of the 
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Figure 5 | M2 receptor inner loop and adaptor protein rearrangement 
and downstream signalling. (a) Intracellular loop rearrangement on 
receptor activation was determined as a change in FRET in HEK293 
cells transfected to stably express a n-FLAG-tagged hm2 FlAsH–eCFP 
fusion protein. maximum FRET induced by 100 µm ACh was set 100%. 
Data are means and s.e.m. from 12–15 cells of at least three independent 
experiments. (b) m2 receptor-mediated conformational change of the 
Gαi-subunit relative to the βγ-subunit was measured as an indicator of 
G-protein activation in Cos-7 cells transfected to transiently coexpress the 
hm2 receptor, Gαi1-91Rluc and GFP10-Gγ2 along with the complementary 
subunit Gβ1. maximum BRET on ACh exposure (100 µm) was set 100%. 
Data are means and s.e.m. from at least four independent experiments. 
(c) m2 receptor-mediated ERK1/2 activation was assessed in live CHo-
hm2 cells using a htrf-based sandwich immunoassay. maximum FRET 
induced by 100 µm ACh was set 100%. Data are means and s.e.m. from 
four independent experiments. (d) β-Arrestin recruitment on m2 receptor 
activation was captured in a BRET-based proximity assay using a stable 
HEK-293-GFP2-β-arr2 cell line transfected to transiently coexpress the 
hm2 receptor–Rluc fusion protein and GRK2. Ligand-promoted BRET was 
normalized to 100 µm ACh. Data are means and s.e.m. from at least three 
independent experiments. Applied ligand concentrations—unless indicated 
otherwise—were 100 µm except for iperoxo 1 µm, iper-8-phth 10 µm and 
iper-8-naph 10 µm., (***P < 0.001, **P < 0.01) significantly different from 
ACh 100 µm, ( +++ P < 0.001) significantly different from iper-6-phth and 
iper-6-naph, respectively, (###P < 0.001, ##P < 0.01, #P < 0.05) significantly 
different from vehicle according to one-way AnoVA and Bonferroni’s 
multiple comparison test.
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Figure 6 | Recovery of Gi signalling of dualsteric probes in the allosteric 
M2 W4227.35A receptor mutant. (a,b) Equilibrium cell surface receptor 
binding of ACh, iperoxo, iper-6-phth and iper-6-naph competing 
against [3H]nms in live CHo-hm2 cells (open symbols) and CHo-hm2 
W4227.35A cells (filled symbols). Data are means ± s.e.m. from at least 
three independent experiments conducted in triplicates. Binding curve 
fitting was based either on the four-parameter logistic function or on the 
allosteric ternary complex model in case of iper-6-phth wild type (WT) 
and iper-6-naph WT. Binding constants for the m2 WT receptor and 
m2 W422A mutant receptor were 5.86 ± 0.04 and 4.36 ± 0.02 for ACh, 
7.49 ± 0.16 and 6.81 ± 0.01 for iperoxo, 6.11 ± 0.06 and 5.45 ± 0.09 for iper-
6-phth and 7.07 ± 0.08 and 6.05 ± 0.04 for iper-6-naph, respectively.  
(c,d) m2 receptor-mediated Gi protein activation was measured as 
reflected by [35s]GTPγs binding to membranes of CHo-hm2 cells (open 
symbols) and CHo-hm2 W4227.35A cells (filled symbols). maximum  
G-protein activation induced by ACh was set 100%. Data are means ±  
s.e.m. from at least three independent experiments conducted in 
quadruplicates. Curve fitting in c and d was based on the operational  
model of agonism using the ligand-binding affinities derived from a and b.  
(e) Coupling efficiencies of indicated ligands at the m2 WT receptor  
and the m2 W4227.35A receptor mutant. (***P < 0.001, *P < 0.05), 
significantly different from iperoxo at the m2 WT receptor according  
to two-way AnoVA with Bonferroni’s multiple comparison test, ns,  
not significantly different from iperoxo at the mutant receptors.
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muscarinic receptor. M2-W4227.35 has been suggested to form 
a link with M2-Y1775.32 of the second extracellular loop and to 
undergo a conformational rearrangement on receptor activation29. 
Interestingly, comparison of the crystal structures of the inactive 
and the active β2 receptor revealed that receptor activation involves 
a movement of the corresponding β2-Y3087.35 towards β2-F1935.32 
of the second extracellular loop, thereby narrowing the free volume 
above the orthosteric site10. Our strategy of probing conformational 
freedom including the ‘rescue mutant’ M2 W4227.35A demonstrates 
that the corresponding region of the M2 receptor is critical for 
G-protein coupling.
The physiological function of allosteric binding areas of class A 
7TMR is only beginning to be understood. Evidence for a mecha-
nism of general importance has recently been provided for β1 and 
β2 adrenergic receptors. Molecular dynamics simulations imply 
that ligand entry into and exit from the orthosteric site is a two-
step event that includes intermediate ligand binding to a vestibule 
formed in the receptor’s extracellular domains50,51. The first step, 
entry into the vestibule, appears to be important for the removal of 
water molecules from the ligand50. The subsequent passage leading 
from the allosteric vestibule into the orthosteric-binding cavity of 
the β2 receptor is lined by β2-Y3087.35 and β2-F1935.32 (ref. 50). As 
these epitopes are rearranged in the course of the inactive-to-active 
receptor transition10, it is likely that this rearrangement occurs par-
allel to or is even caused by the ligand moving along the passage into 
the orthosteric site. Our findings disclose that spatial rearrangement 
of this passage in the M2 receptor is critical for receptor movements 
required for appropriate unfolding of the intracellular domain 
region for G-protein coupling. In particular, we show that the allos-
teric vestibule of the muscarinic M2 receptor has to provide room 
for a ‘standard’ conformational rearrangement allowing Gi coupling 
and an ‘extended’ movement for Gs coupling. Beyond that we show 
that the Gs activation-competent receptor conformation is reached 
via an intermediate conformation with full efficacy for Gi activation. 
Hence, for the first time we assign a biological role to the allosteric 
vestibule for controlling G-protein signalling of a 7TMR.
Crystal structures of active class A 7TMRs point to a common 
activation mechanism including cytosolic outwards movement of 
transmembrane helices and a corresponding inwards movement 
of extracellular domains9–11. In the end, the novel chemical– 
biological strategy introduced here offers a widely applicable 
label-free approach for clarifying the dependence of promiscu-
ous signalling pathway activation on extracellular domain rear-
rangements. This does not only apply to 7TMRs that are already 
known to bind allosteric or even dualsteric ligands52. The new strat-
egy will be of even broader relevance if the extracellular vestibule- 
mediated ligand-binding process represents a more general 
mechanism50,51.
With respect to drug discovery, our findings likely disclose a 
general route for the design of a new type of biased agonist. It is 
unique as it addresses two distinct receptor sites simultaneously with 
opposing functional messages, that is activation of the orthosteric 
receptor region by the agonist moiety and inactivation of an allos-
teric domain by an antagonist or even inverse agonist moiety29,53. 
When applied un-tethered, the components reveal strong negative 
binding cooperativity as previously shown with orthosteric ACh 
and allosteric naph- or phth-residues29 reflecting a severe confor-
mational mismatch. On covalent linkage of these building blocks, 
dualsteric binding is enforced leading to a receptor conformation, 
which is unlikely to occur with un-tethered ligands and has spe-
cific signalling properties. The choice of building blocks and linker-
length allows designing custom-made receptor activators endowed 
with desired signalling phenotypes.
We conclude that the allosteric vestibule serves to fine-tune the 
nature of signals generated on orthosteric ligand activation of a 
7TMR. The activation of differential signalling pathways piloted by 
extracellular domains is due to sequential conformational states of 
the receptor protein and eventually results in a hierarchical order 
of intracellular adaptor protein recruitment. As several family A 
7TMRs harbour an allosteric vestibule within their outer domains, 
the findings also suggest that controlling G-protein coupling is a 
general biological role of 7TMR allosteric vestibules.
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Figure 7 | Gs signalling of dualsteric probes is augmented in the 
W4227.35A mutant. (a,c) maximum Gi- and Gs-DmR effects of 
the indicated compounds in wild-type CHo-hm2 cells (a) or CHo-
hm2 W4227.35A cells (c). Data represent means ± s.e.m. from three 
independent experiments in a and c. Cells were pretreated with PTX 
100 ng ml − 1 for 16–24 h to disclose Gs signalling. All concentrations used 
provide maximum effects for both the Gi and the Gs pathway according to 
GTPγs binding and cAmP accumulation assays, respectively. Data were 
normalized on the respective effect of iperoxo 10 µm, which was set 100% 
for each condition. Dashed lines represent balanced agonism. Continuous 
lines define a binodal curve resulting from a best fit to the indicated data 
points in a. Concentrations of ligands: iperoxo 10 µm, iper-6-phth (i-6-p) 
100 µm, iper-8-phth (i-8-p) 10 µm, iper-6-naph (i-6-n) 100 µm, iper- 
8-naph (i-8-n) 10 µm, pilocarpine 100 µm and mcn-A-343 100 µm.  
(b) Iper-6-phth and iper-6-naph induce significant Gs signalling at  
the hm2 W4227.35A mutant in contrast to wild-type receptors. shown 
are maximal DmR responses normalized to the DmR of iperoxo 10 µm 
(set 100%) in CHo-hm2 cells (wild type, open bars) and CHo-hm2 
W4227.35A cells (filled bars). Data are means ± s.e.m of at least three 
independent experiments. *P < 0.05,**P < 0.01, ***P < 0.001, significant 
to vehicle according to a two-way AnoVA with Bonferroni’s multiple 
comparison test.
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Methods
Cell culture. Flp-In-Chinese hamster ovary cells (Flp-In-CHO) stably expressing 
the hM2 receptor (CHO-hM2 cells) or the hM2 W422A mutant receptor (CHO-
hM2 W422A cells) and CHO-K1 cells were cultured in Ham’s nutrient mixture 
F-12 supplemented with 10% (v/v) fetal calf serum (FCS), 100 U ml − 1 penicillin, 
100 µg ml − 1 streptomycin and 2 mM l-glutamine. COS-7 cells were grown in 
DMEM supplemented with 10% (v/v) FCS, 100 U ml − 1 penicillin and 100 µg ml − 1 
streptomycin. HEK293 cell clones stably expressing either GFP2-β-arr2 or the 
hM2 receptor FRET-sensor, respectively, were maintained in DMEM supple-
mented with 10% (v/v) FCS, 100 U ml − 1 penicillin, 100 µg ml − 1 streptomycin and 
200–500 µg ml − 1 G418. All cell lines were kept at 37 °C in a humidified 5% CO2 
atmosphere (7% CO2 for HEK293 cells stably expressing the hM2 FRET-sensor).
Radioligand-binding assay. CHO-hM2 and CHO-hM2 W422A cells were seeded 
on cell culture dishes and grown for 2 days. For PTX experiments, cells were pre-
treated with PTX (100 ng ml − 1) for 16–24 h before the assay. Cells were collected 
and adjusted to give a final concentration of 750,000 cells per ml in assay buffer 
(Hank’s balanced salt solution (HBSS) supplemented with 20 mM HEPES; pH 7.0). 
All experiments were carried out with 75,000 cells per well in a 96-well microtit-
erplate (Abgene, Germany) at 28 °C in a final volume of 500 µl. Experiments were 
terminated by rapid vacuum filtration and bound radioactivity was determined  
by solid scintillation counting.
For two-point kinetic dissociation experiments, cells were pre-incubated with 
2 nM [3H]NMS for 45 min before addition of dualsteric compounds. Reassociation 
of [3H]NMS was prevented by 10 µM atropine and reactions were terminated  
after 10 min.
For equilibrium binding experiments, cells were incubated for 4 h with 0.2 nM 
[3H]NMS and agonists at different concentrations to reach equilibrium. To make 
sure that binding equilibrium was attained in presence of dualsteric compounds, 
incubation time was calculated as described previously23.
DMR assay. DMR assays were performed on a beta version of the Corning Epic 
biosensor. A detailed protocol is published elsewhere33. Briefly, CHO-hM2 wild-
type, CHO-hM2W422A cells and CHO-K1 cells transfected to transiently express 
the hM2 wild-type receptor or a FLAG-tagged hM2 receptor–Rluc fusion protein 
were grown to confluence for 20–24 h on Epic biosensor 384-well microplates. 
Cells were washed twice with HBSS containing 20 mM HEPES (pH 7.0) and kept 
for 2 h in the Epic reader at 28 °C. DMR was monitored before (baseline read) 
and after the addition of compound solutions for 3,600 s. Pre-incubation time for 
CTX (100 ng ml − 1) pretreatment and PTX (100 ng ml − 1) pretreatment was 8 and 
16–24 h, respectively.
[35S]GTPS-binding assay. [35S]GTPγS-binding experiments were conducted 
as described previously24,29,32. In brief, homogenates of membranes of CHO-hM2 
wild-type or CHO-hM2W422A cells (40 µg ml − 1) were incubated with 0.07 nM 
[35S]GTPγS and maximum agonist-induced [35S]GTPγS incorporation was  
measured after 1 h.
cAMP accumulation assay. Agonist-induced rise of intracellular cAMP was cap-
tured in CHO-hM2 cells pretreated with 50 ng ml − 1 PTX for 16–24 h as described 
previously54 using the HTRF-cAMP dynamic kit (Cisbio, Bagnols-sur-Cèze, 
France) following the manufacturer’s instructions. Fluorescence was quantified  
on a Mithras LB 940 reader (Berthold Technologies, Bad Wildbad, Germany).
ERK1/2 phosphorylation assay. Quantification of phosphorylated ERK1/2  
levels was performed using the HTRF-Cellul’erk kit (Cisbio). CHO-hM2 cells 
were seeded into 96-well plates at a density of 40,000 cells per well and cultured 
overnight. For PTX pretreatment, cells were dispensed in medium containing 
100 ng ml − 1 PTX. The next day, cells were washed twice in HBSS buffer supple-
mented with 20 mM HEPES and starved for 4 h in serum-free medium. After  
starvation, cells were incubated with agonists diluted in medium for 10 min at 
37 °C. Following treatment, agonists were removed and cells were lysed in 50 µl  
of the supplemented lysis buffer. The plates were incubated for 10 min at room  
temperature with shaking to lyse the cells and then frozen overnight at  − 20 °C. 
Lysates (16 µl) were transferred to a white 384-well plate. Anti-phospho-ERK1/ 
2-d2 (2 µl) and anti-ERK1/2-Eu3 +  − Cryptate (2 µl) were added to each well and 
plates were incubated in the dark for 2 h at room temperature. Time-resolved FRET 
signals were measured after excitation at 320 nm using the Mithras LB 940 multi-
mode reader (Berthold Technologies). Data analysis was based on the fluorescence 
ratio emitted by the d2-labelled anti-phospho-ERK1/2 (665 nm) over the light 
emitted by the Eu3 + -Cryptate-labelled anti-ERK1/2 (620 nm). Levels of phosphory-
lated ERK1/2 were normalized to those obtained by 100 µM ACh.
BRET assay. β-Arrestin2 recruitment assays were performed on HEK293 cells 
stably expressing GFP2-β-arr2 and transiently coexpressing the human M2  
receptor–Rluc fusion protein and GRK2. For measurement of G-protein subunit 
rearrangements, COS-7 cells transiently coexpressing the hM2 receptor, Gαi1-
91Rluc, GFP10-Gγ2 along with the complementary subunit Gβ1 were used.  
Forty-eight hours after transfection, cells were detached and resuspended in  
HBSS with 20 mM HEPES at a density of 1.06×106 cells per ml. Cell suspension 
(170 µl) was distributed in white 96-well microplates and incubated in the presence 
of 10 µl buffer or agonist for 2 min (β-arrestin2 recruitment) or 1 min (G-protein 
activation) before substrate addition. DeepBlueC coelenterazine (Gold Biotechnol-
ogy, MO, USA; 20 µl per well) was injected by injector 3 to yield a final concentra-
tion of 5 µM. To detect BRET, light emission at 400 and 515 nm was measured 
sequentially using a Mithras LB 940 instrument. The BRET signal (milliBRET  
ratio) was determined by calculating the ratio of the light emitted by the fluores-
cence acceptor (515 nm) and the light emitted by Rluc (400 nm).
FlAsH labelling and single cell-FRET measurements. FlAsH labelling was per-
formed as published previously43. In brief, cells were grown to near confluence on 
glass coverslips. Cells were washed twice with labelling buffer containing 150 mM 
NaCl, 10 mM HEPES, 2.5 mM KCl, 4 mM CaCl2, 2 mM MgCl2 supplemented with 
10 mM glucose (pH 7.3). After incubation with labelling buffer supplemented with 
500 nM FlAsH and 12.5 µM 1,2-ethanedithiol (EDT) at 37 °C for 1 h, cells were 
flushed twice with labelling buffer. To reduce non-specific binding, the cells were 
again incubated for 10 min with labelling buffer supplemented with 250 µM EDT. 
Finally, the cells were rinsed twice with labelling buffer.
FRET measurements were performed using a Zeiss Axiovert 200 inverted 
microscope endued with a PLAN-Neofluar oil immersion 100-objective, a dual 
emission photometric system and a Polychrome IV light source (Till Photonica, 
Gräfelfing, Germany) as described previously42,44. Experiments were conducted  
at room temperature using live HEK293 cells stably expressing the hM2 receptor  
FRET-sensor that were maintained in assay buffer. Single cells were excited at 
436 nm (dicroic 460 nm) with a frequency of 10 Hz. Emitted light was recorded 
using 535/30 nm and 480/40 nm emission filters and a DCLP 505 nm beam splitter 
for FlAsH and CFP, respectively. FRET was observed as the ratio of FlAsH/CFP, 
which was corrected offline for bleedthrough, direct FlAsH excitation and photo-
bleaching using the 8.0 version of the Origin software as described recently44.  
To investigate changes in FRET on ligand addition, cells were continuously 
superfused with FRET buffer complemented with various ligands in saturating 
concentrations as indicated. Superfusion was done using the ALA-VM8 (ALA 
Scientific Instruments).
Calculations and data analysis. Quantification of probe-induced DMR signals 
was based on the signal’s peak value between 500 and 1,200 s. All DMR recordings 
were solvent corrected.
All nonlinear regression analyses were performed using Prism 5.01 (GraphPad 
Software, San Diego, CA). Equilibrium binding data from ACh, iperoxo, iper-6 
and iper-8-phth were analysed by a four-parameter logistic function yielding IC50 
values, which were subsequently converted into apparent equilibrium dissociation 
constants Ki using the Cheng-Prusoff correction as described previously24. In case 
of allosteric incomplete displacement of [3H]NMS by iper-6-phth, iper-6-naph 
and iper-8-naph, curve analysis was based on the allosteric ternary complex model 
as described elsewhere24,29. Data obtained from [35S]GPTγS-binding and cAMP 
accumulation assays were subjected to a two-step analysis. First, data were fitted by 
a four-parameter logistic function yielding parameter values for a ligand’s potency 
(pEC50) and maximum effect (Emax). Second, data points were analysed by the 
operational model of agonism37,
E E A
A A K
= ⋅ ⋅[ ]
⋅[ ]+ [ ]+( )
max t
t A
where Emax is the maximal response of the system induced by the maximal effect  
of a full agonist, KA is the equilibrium dissociation constant of the agonist– 
receptor complex and reflects affinity, and τ is the ‘coupling efficiency’, which  
indicates how efficient agonist binding is transduced into a signalling response  
and therefore reflects agonist efficacy. For quantification of ligand bias, we used  
a scale log(τ/KA) that comprises information about both affinity and efficacy of  
the respective agonist for activating a signalling pathway38. These transduction 
coefficients were then expressed relative to ACh for each pathway according to
∆ log( / ) log( / )
log( /
, ,t t
t
K K
K
A agonist pathway A agonist pathway=
− A ACh pathway) ,
To offset the effects of system bias and to display true ligand bias, a ‘Log bias’ scale 
is given by
∆∆ ∆
∆
log( / ) log( / )
log( / )
,t t
t
K K
K
A agonist A agonist pathway
A ag
=
−
1
onist pathway, 2
Computation of transduction coefficients, ratios thereof and the bias factors 
included error propagation.
(1)
(2)
(3)
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Statistical analysis. Data are shown as means ± s.e.m for n observations.  
Comparisons of groups were performed using one-way ANOVA or two-way 
ANOVA with Bonferroni’s multiple comparison test. 
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